Fibromyalgia
Conditions
Interventions
Patients with fibromyalgia will be randomly allocated to treatment with placebo (Group I, 30 patients) or allopurinol (Group II, 30 patients) with a 4-week follow-up. The treatment will be administere
Drug
Sponsors
Hospital de Clinicas de Porto Alegre
Hospital de Clinicas de Porto Alegre
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Female gender; age between 18 and 65 years; functional status class I or II according to the American Society of Anesthesiologists (ASA); patients with fibromyalgia
Exclusion criteria
Exclusion criteria: Previous diagnosis of schizophrenia and other psychotic disorders; history of bipolar disorder; diagnosis of delirium; history of stroke; previous diagnosis of CNS neoplasia; deficit in cognitive or motor development; patients with dialysis renal failure; patients with gout or lithiasic kidney disease; patients who do not understand the Portuguese language or who are illiterate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the adjuvant analgesic efficacy of oral allopurinol versus placebo associated with conventional treatment in patients with refractory fibromyalgia. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the influence of allopurinol compared to placebo in improving symptoms of anxiety and depression associated with fibromyalgia. | — |
Countries
Brazil
Contacts
Public ContactAndré Schmidt
Hospital de Clinicas de Porto Alegre
Outcome results
None listed